CERC - Cerecor Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.0000
+0.6300 (+18.69%)
At close: 4:00PM EST

4.0000 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close3.3700
Open3.4400
Bid3.6000 x 1300
Ask4.0000 x 1300
Day's Range3.4400 - 4.0350
52 Week Range2.7100 - 7.6500
Volume101,307
Avg. Volume58,787
Market Cap188M
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Drugmakers raised prices of over 40 prescription drugs
    Yahoo Finance Video

    Drugmakers raised prices of over 40 prescription drugs

    Yahoo Finance’s Adam Shapiro, Sibile Marcellus, and Rick Newman join Direxion Managing Director Sylvia Jablonski to discuss.

  • Cerecor (NASDAQ:CERC) Is Making Moderate Use Of Debt
    Simply Wall St.

    Cerecor (NASDAQ:CERC) Is Making Moderate Use Of Debt

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • What Does Cerecor Inc.'s (NASDAQ:CERC) Balance Sheet Tell Us About It?
    Simply Wall St.

    What Does Cerecor Inc.'s (NASDAQ:CERC) Balance Sheet Tell Us About It?

    While small-cap stocks, such as Cerecor Inc. (NASDAQ:CERC) with its market cap of US$191m, are popular for their...

  • Zacks Small Cap Research

    CERC: CDG FIRST Trial Underway…

    By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Business Update CDG FIRST Trial Underway On July 15, 2019, Cerecor Inc. (NASDAQ:CERC) announced the first patient has been enrolled in ...

  • Benzinga

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • Zacks Small Cap Research

    CERC: Completion of Phase 1 Trial of CERC-801…

    On April 29, 2019, Cerecor Inc. (CERC) announced dosing has completed in the Phase 1 clinical trial of CERC-801 (D-galactose), which is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency. The open label, randomized, single dose, 4-way crossover study in 16 healthy adult volunteers showed CERC-801 to be safe and well tolerated with no reports of serious adverse events. The company has also initiated a natural history study to collect efficacy and safety data from CDG patients treated with monosaccharide replacement therapy, which will be an important part of the application for approval using the 505(b)(2) pathway.

  • Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years
    Simply Wall St.

    Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Vanguard founder Jack Bogle helped spearhead the low-cost index fund, putting average returns w...

  • Zacks Small Cap Research

    CERC: Positive Results for Phase 1 Trial of CERC-301…

    The Phase 1 trial is a double blind, randomized, placebo controlled trial with a target enrollment of 20 Parkinson’s patients with nOH. Each patient will have five visits in which they will receive four single escalating doses of drug (8, 12, 16, or 20 mg) or placebo.

  • Zacks Small Cap Research

    CERC: Multiple Data Readouts in 2019; Commercial Unit Continues Growth…

    Cerecor, Inc. (CERC) is a fully integrated biopharmaceutical company with commercial operations intended to support the development of a pipeline of therapies targeting neurology, pediatric, and orphan indications. The neurology pipeline is led by CERC-301, which is currently in a Phase 1 clinical trial in patients with neurogenic orthostatic hypotenstion (nOH). Cerecor is currently conducting a Phase 1 clinical trial of its lead neurology candidate CERC-301 for the treatment of nOH associated with Parkinson’s disease and other neurodegenerative diseases.

  • Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?
    Simply Wall St.

    Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Cerecor Inc. (NASDAQ:CERC) should be aware ofRead More...